Res Health Serv Reg. 2026 Aug 6;5(1):11. doi: 10.1007/s43999-026-00095-3.
ABSTRACT
INTRODUCTION: More than 90% of the highest incidence rates of cervical cancer occur in sub-Saharan Africa region. However, this region has low uptake of cervical cancer screening compared to other World Health Organization (WHO) regions. Therefore, the current study aimed to show the geographical and regional variation and predictors of low uptake of cervical cancer screening among women aged 30-49 years in Tanzania.
METHODS: This study analyzed data from 2022 Tanzania Demographic and Health Survey and Malaria Indicator Survey (TDHS-MIS). The uptake of cervical cancer screening was the outcome variable which dichotomized into “Yes” for the women who reported a doctor or other healthcare provider ever tested her for cervical cancer otherwise it was coded “No.” Besides, descriptive and geospatial analysis, the mixed-effect multilevel logistic regression analysis was performed to determine predictors of low uptake of cervical cancer screening.
RESULTS: This study included a total of 6911 women between 30 and 49 years old, with the median age (interquartile range) of 38 (34-43) years. The overall uptake of cervical cancer in Tanzania remain low (12.2%). The geospatial analysis indicates the lowest uptake was observed in Southern (4.7%) and Central (5.9%). The random effect model revealed that the variation in uptake of cervical cancer screening, 26% was attributed to between clusters within regions or geographical zones differences [ICC = 0.26, 95%CI; 0.22-0.31]. Fixed effect model revealed that women with older ages, formal education, health insurance coverage, employed for cash, being in rich household, listen to radio, reading newspapers, magazines, or using the internet had higher odds of uptake cervical cancer screening than their counterparts.
CONCLUSION: For realization of WHO target on elimination of cervical cancer by screening 70% of all eligible women age 30 and above by 2030, more efforts on addressing social determinants of health and provision of health education through mass media should be considered.
CLINICAL TRIAL NUMBER: Not applicable.
PMID:42560633 | DOI:10.1007/s43999-026-00095-3
